September marks the beginning of the second conference cycle for VIVEbiotech
During this month, we will be attending three leading international advanced therapies events to share insights, strengthen partnerships, and connect with key industry stakeholders.
As summer comes to an end, VIVEbiotech is getting ready to kick off a busy conference season with participation in three major international events focused on advanced therapies. Over the coming weeks, we will be in Barcelona, Boston, and Bilbao to meet with partners, customers, and industry professionals, exchange insights, and showcase our expertise in lentiviral vector development and manufacturing.
Our first stop will be Advanced Therapies Europe by Phacilitate, taking place in Barcelona from September 7-9, where we will participate as a Bronze Sponsor. In addition, on September 9 from 1:30 PM to 2:30 PM, we will lead the panel discussion From Early Development to Commercial Readiness: Real-World Lessons in Advancing Lentiviral-Based Therapies.
We will then continue our event schedule at the CAR-TCR Summit by Hanson Wade, taking place September 15-17 in Boston, USA.
The season will continue with our participation in BIOSPAIN 2026 by AseBio, held September 29 to October 1 in Bilbao. As a Bronze Sponsor, VIVEbiotech will also participate in two roundtable discussions:
- Making ATMPs Sustainable in 2026: What Gets Funded, Scaled, and Acquired?
September 29 | 4:00 PM – 4:45 PM - From Platform to Patient: Scaling Biotech and Advanced Therapies Through Integrated CDMO Ecosystems
September 30 | 11:30 AM – 12:15 PM
We look forward to these opportunities to connect with the international advanced therapies community, explore new collaborations, and continue contributing to the development of innovative treatments for patients.